Antazoline, naphazoline
Sold as Antistin-privin, Optallerg
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Background
Registration
- Applicants
- 2
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Novartis South Africa (Pty) Ltd | Antistin-privin | Not stated | H1124 | Not determined | None |
| Pharmacare limited û woodmeadCancelled | Optallerg | Not stated | L0386 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Antistin-privin 1 ML ANTAZOLINE A 5 MG NAPHAZOLINE NITRATE A 0,25 MG | Not listed | H1124 | Old Medicine | Not determined | None |
| Optallerg EACH 10 CONTAINS ANTAZOLINE SULFATE 50 mg NAPHAZOLINE NITRATE 2,5 mg | Not listed | L0386L/15.4/386 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S2: Antazoline
Consolidated Schedules 06 July 2026, line 1590
S2: Naphazoline
- except when intended for nasal use.
Consolidated Schedules 06 July 2026, line 2366
S1: Naphazoline
- when intended for nasal use.
Consolidated Schedules 06 July 2026, line 864
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.